The New York-based pharmaceutical giant recently announced it would launch its Inflectra drug in the U.S. nearly two years earlier than expected, which BMO Capital Markets analyst Alex Arfaei called "incrementally positive." The drug, which is a biosimilar to Janssen Biotech's Remicade, can be used for Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis (arthritis of the spine), psoriatic arthritis and chronic severe plaque psoriasis.
Arfaei noted the earlier-than-expected launch of the drug (approved in April of this year), is a sign that it's confident against any patent litigation with Remicade. "We have moved our Inflectra U.S. forecast up from 2018 to 4Q16 and now forecast 2017 U.S. sales of $243MM," the analyst wrote to clients. "Ex- US we continue to forecast Inflectra sales of $355MM in 2017."
Pfizer shares have gained less than 1% since the start of the year and are down nearly 8% over the past year (excluding dividends), compared to a 4% rise in the S&P 500.
Leerink analyst market analysts led by Seamus Fernandez are expecting to hear more information about the company's Ibrance drug, used for breast cancer. "We note that on the 2Q conference call, [management] disclosed that Ibrance has penetrated ~43% of 1L, ~46% of 2L and ~24% of 3L," Fernadez wrote in a note to clients. "We expect further growth in 1L to drive sustained growth due to the longer treatment duration (~>1year) compared to the 2/3L setting (a few months)."
Analysts surveyed by Yahoo! Finance expect the company to earn 62 cents a share on $13.05 billion in revenue.
These three ETFs may benefit if investors like what Pfizer has to say about the past 90 days.
iShares U.S. Pharmaceuticals ETF
Jefferies analyst Dr. Jeffrey Holford recently downgraded shares to hold, noting that Ibrance and Prevnar have largely been baked into the stock and the company's proposed tax inversion and the speculation it would separate its Global Established Pharma business never materialized.
With that in mind, there's increased speculation that Pfizer may make another purchase to keep its growth engine running. "We have lowered our [price target] to $36 from $39 and reduced our rating from Buy to Hold as a result of these changes and our view that the risk of major M&A action by [Pfizer] over the next 12 months or so has increased," Holford wrote in a note to clients.
iShares U.S. Consumer Services ETF
Leerink's Fernandez said he expects to hear more about Ibrance's entrance into 1L breast cancer "to drive sustained growth due to the longer treatment duration (~>1year) compared to the 2/3L setting (a few months)."
Health Care Select Sector SPDR Fund ETF